Revolution Medicines, Inc.
Clinical trials sponsored by Revolution Medicines, Inc., explained in plain language.
-
New hope for pancreatic cancer: targeted drug enters final testing phase
Disease control OngoingThis phase 3 trial tests a new drug called daraxonrasib (RMC-6236) against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug o…
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC